Salute e Benessere
Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology
This marks the first clinical study from the Alys pipeline, which includes a broad portfolio of assets targeting unmet needs in additional indications such as atopic dermatitis, chronic spontaneous urticaria, vitiligo, or systemic mastocytosis. The Company remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027.
ALY-101 is the first clinical candidate to emerge from a multi-year joint research between Alys and the RNA Institute of UMass Chan Medical School, focused on developing siRNA therapies for dermatological use.
Alys Pharmaceuticals, Inc. ("Alys") is a Boston and Lausanne-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich ), Craig Mello (UMass Chan Medical School), Eric Deutsch ( Gustave Roussy ) and Mark Prausnitz ( Georgia Institute of Technology ). Alys is led by dermatology specialist, co-founder and COO Thibaud Portal .
It was formed from the aggregation of 6 asset-centric Medicxi companies – Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.
Its pipeline includes programs targeting multiple dermatological indications, including atopic dermatitis, vitiligo, psoriasis and mastocytosis. The Company is entering the clinic with the siRNA platform developed by Aldena Therapeutics, which offers the potential for long-lasting treatments that could transform the dermatology treatment landscape. In addition, Alys is advancing its mastocyte-selective therapies developed by Granular Therapeutics, with CTA/IND expected in 2025.
For further information, please visit www.alyspharma.com.
View original content:https://www.prnewswire.co.uk/news-releases/alys-pharmaceuticals-receives-ind-clearance-for-phase-2a-trial-of-first-genetic-medicine-program-in-dermatology-302366493.html